Leerink Partners analyst Jonathan Chang has maintained their bullish stance on IMTX stock, giving a Buy rating on November 6. Jonathan ...

Immatics (IMTX) has released an update. Immatics is showcasing promising advancements in its TCR-T therapy candidates targeting PRAME, with significant responses in metastatic melanoma patients and ...

Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock To get a sense of who is truly in control of Immatics N.V. (NASDAQ:IMTX), it is ...

Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock To get a sense of who is truly in control of Immatics N.V. (NASDAQ:IMTX), it is ...

Its latest – with Immatics – bolsters its immuno-oncology business and could be worth more than $1.5 billion. Immatics is a specialist in T cell receptor (TCR) therapeutics, an emerging area ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

Immatics (NASDAQ:IMTX – Get Free Report) was the recipient of a significant drop in short interest during the month of September.As of September 30th, there was short interest totalling ...

The stock of Immatics N.V (IMTX) has seen a -14.00% decrease in the past week, with a -25.04% drop in the past month, and a -25.64% decrease in the past quarter. The volatility ratio for the week is 6 ...

Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen.